iBio logo
iBio IBIO
$ 1.19 1.24%
report update icon

Quarterly report 2026-Q4
added 08-28-2026

iBio Income Statement 2026-2010 | IBIO

Brief overview of profit and loss at iBio

The figures are compared over a five-year interval. According to figures from iBio, revenue changed from $1.6 million to $400 thousand over five years. The total change was −75.6%, with a CAGR of approximately −24.6%. The business finished the period with a smaller revenue base.

The five-year EBITDA result moved by −54%: from −$11.8 million to −$18.1 million. Operating profitability strengthened faster than the scale of sales. Comparing the endpoints gives EBITDA margins of −718.1% and −4529.5%. A lower EBITDA share weakens the quality of the result.

The net financial result changed from −16.4 million dollars to −18.4 million dollars. Profitability deteriorated further over the five years.

Conclusion

The indicators point to a weaker financial profile. Caution is warranted because of a narrow EBITDA buffer, a declining EBITDA margin and a softer top-line trend. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement iBio

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

142 M 60.6 M 7.55 M 177 K 22.2 M - 294 M 13.1 M 8.72 M 27.6 M 50.2 M 46.5 M 24.6 M 24.7 M 46.6 M 83.3 M -

Shares

104 M 10.5 M 3.83 M 612 K 8.72 M 7.82 M 62.8 M 18.9 M 10.6 M 8.91 M 8.1 M 7.15 M 6.3 M 4.94 M 3.95 M 3.1 M -

Historical Prices

1.36 5.77 1.97 0.29 2.54 0.48 1.6 0.28 0.87 1.7 4 6 4.8 5.8 6.8 8.5 5.45 K

Net Income

-33 M -18.4 M -24.9 M -65 M -50.3 M -23.2 M -16.4 M -17.6 M -16.1 M -14.5 M -9.76 M -6.62 M -3.67 M -6.2 M -5.68 M -12.1 M -

Revenue

100 K 400 K 225 K - 1.88 M 2.37 M 1.64 M 2.02 M 444 K 394 K 948 K 1.85 M 205 K 1.01 M 1.28 M 520 K -

Cost of Revenue

- - - - 216 K 1.46 M 703 K - - - - - - - - - -

Gross Profit

- - - - 2.17 M 909 K - - - - - - - - 1.28 M 520 K -

Operating Income

-35.1 M -18.6 M -16.6 M -29.3 M -29.7 M -31.1 M -14 M -15.8 M -14.2 M -14.3 M -9.89 M -6.67 M -3.84 M -6.67 M -9.33 M -9.65 M -

Interest Expense

- - - 83 K 1.41 M 2.45 M 2.47 M 1.9 M 1.92 M 1.93 M 807 K - - 90 K 63 K 50.5 K -

EBITDA

-34.6 M -18.1 M -16 M -28.7 M -27.4 M -30.6 M -11.8 M -14 M -12.5 M -12.6 M -8.95 M -6.3 M -3.48 M -6.33 M -9 M -9.28 M -

Operating Expenses

35.2 M 19 M 16.9 M 29.3 M 31.6 M 32 M 15.6 M 17.8 M 14.7 M 14.7 M 10.8 M 8.52 M 4.04 M 7.67 M 10.6 M 10.2 M -

General and Administrative Expenses

10.6 M 10.7 M 11.7 M 19 M 21.8 M 22 M 12.4 M 12.3 M 10.7 M 10.6 M 7.68 M 5.02 M 4.2 M 4.24 M 5.62 M 7.09 M -

All numbers in USD currency

Quarterly Income Statement iBio

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 120 M 99.1 M 53 M 99.1 M 53 M 19.3 M 9.86 M 9.13 M 8.63 M 8.62 M 3.71 M 1.86 M 1.2 M 1.02 M 659 K 490 K 8.84 M 8.73 M 8.72 M 8.72 M 8.72 M 8.72 M 216 M 188 M 162 M 188 K 162 K 36.9 K 21.9 K 36.9 K 21.9 K 18.7 K 17.9 K 18.7 M 17.9 M 9.66 M 9.18 M 96.6 M 91.9 M 89.1 M 89.1 M 89.1 M 89.1 M 77.3 M 77.3 M 77.3 M 77.3 M 71 M 65.9 M 68.4 M 65.6 M 64 M 56.7 M 64 M 56.7 M 47.8 M 47.8 M 47.8 M 47.8 M 32.4 M 32.4 M 32.4 M 32.4 M

Net Income

- -7.73 M -8.99 M -5.72 M -8.99 M -5.72 M - -4.86 M -4.36 M -3.99 M - -3.17 M -8.21 M -5.75 M - -7.29 M -33.6 M -18.1 M -51.7 M -12.4 M -11.9 M -8.94 M -20.9 M -7.66 M -8.13 M -7.53 M -8.13 M -7.53 M -3.76 M -4.46 M -3.76 M -4.46 M -4.47 M -4.4 M -4.47 M -4.4 M -3.9 M -3.83 M -3.9 M -3.83 M -3.23 M -3.06 M -3.23 M -3.06 M -2.25 M -1.8 M -2.25 M -1.8 M -1.65 M -1.41 M -1.65 M -1.41 M -1.62 M 379 K -1.62 M 379 K -1.07 M -2.05 M -1.07 M -2.05 M -1.6 M 383 K -1.6 M 383 K

Revenue

- 100 K - 100 K - 100 K - - 200 K - - - - 50 K - - - - - 1.8 M 168 K 84 K 84 K 765 K 705 K 410 K 705 K 410 K 314 K 108 K 314 K 108 K 651 K 45 K 651 K 78 K 153 K 122 K 275 K 37 K 75 K 135 K 75 K 135 K 134 K 160 K 134 K 160 K 367 K 819 K 367 K 819 K - - - - - 390 K 390 K 390 K 234 K 320 K 234 K 320 K

Cost of Revenue

- - - - - - - - - - - - - - - - - - - 48 K 113 K 40 K 153 K 493 K 211 K 107 K - 86 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - 1.9 M 55 K 171 K 226 K 272 K 494 K 303 K - 10 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -8.36 M -9.44 M -5.95 M -9.44 M -5.95 M - -4.88 M -4.42 M -4.11 M - -3.63 M -4.5 M -5.1 M - -6.17 M -10.6 M -7.64 M -18.2 M -6.79 M -7.23 M -5.22 M -12.5 M -7.2 M -7.54 M -6.92 M -7.54 M -6.92 M -3.16 M -3.86 M -3.16 M -3.86 M -4.02 M -3.95 M -4.02 M -3.95 M -3.43 M -3.36 M -3.43 M -3.36 M -3.32 M -3.15 M -3.32 M -3.15 M -2.25 M -1.81 M -2.25 M -1.81 M -1.67 M -1.42 M -1.67 M -1.42 M -1.64 M 240 K -1.64 M 240 K -1.7 M -1.81 M -1.7 M -1.81 M -2.67 M -2.33 M -2.67 M -2.33 M

Interest Expense

- - - - - - - - - - - 52 K 34 K 26 K - 35 K 31 K - 31 K 250 K 328 K 609 K 937 K 612 K 615 K 614 K 615 K 614 K 615 K 620 K 615 K 620 K 476 K 476 K 476 K 476 K 479 K 480 K 479 K 480 K 483 K 483 K 483 K 483 K - - - - - 3 K - - - - - 15 K 17 K 15 K 17.5 K 15.4 K 16.8 K 9.58 K 16.8 K 9.58 K

EBITDA

- -7.95 M -9.18 M -5.83 M -9.44 M -5.83 M - -4.87 M -4.41 M -3.99 M - -3.62 M -4.49 M -4.94 M - -6.16 M -10.5 M -7.36 M -17.8 M -6.67 M -7.11 M -4.92 M -11.6 M -7.08 M -7.43 M -6.83 M -7.43 M -6.83 M -3.08 M -3.79 M -3.02 M -3.79 M -3.84 M -3.77 M -3.84 M -3.59 M -3.09 M -3.02 M -3.09 M -3.02 M -3 M -2.83 M -3 M -2.83 M -2.25 M -1.81 M -2.25 M -1.81 M -1.58 M -1.42 M -1.66 M -1.42 M -1.55 M 241 K -1.64 M 241 K -1.61 M -1.73 M -1.53 M -1.73 M -2.59 M -2.25 M -2.51 M -2.25 M

Operating Expenses

- 8.36 M 9.44 M 6.05 M 9.44 M 6.05 M - 4.88 M 4.62 M 4.11 M - 3.63 M 4.5 M 5.15 M - 6.17 M 10.6 M 7.64 M 18.2 M 8.59 M 7.23 M 5.31 M 12.5 M 7.48 M 8.04 M 7.23 M 8.25 M 7.33 M 3.47 M 3.96 M 3.47 M 3.96 M 4.67 M 4 M 4.67 M 4 M 3.58 M 3.48 M 3.58 M 3.48 M 3.4 M 3.29 M 3.4 M 3.29 M 2.39 M 1.97 M 2.39 M 1.97 M 2.03 M 2.24 M 2.03 M 2.24 M 1.64 M -240 K 1.64 M -240 K 1.7 M 2.2 M 1.7 M 2.2 M 2.91 M 2.65 M 2.91 M 2.65 M

General and Administrative Expenses

- 5.11 M 5.16 M 2.5 M 5.16 M 2.5 M - 2.97 M 2.74 M 2.8 M - 2.72 M 2.96 M 3.55 M - 3.52 M 7.79 M 5.09 M 12.9 M 5.32 M 5.37 M 4.18 M 9.55 M 5.31 M 5.66 M 5.36 M 5.81 M 5.57 M 2.58 M 2.99 M 2.58 M 2.99 M 3.39 M 2.87 M 3.39 M 2.87 M 2.59 M 2.5 M 2.59 M 2.5 M 2.35 M 2.47 M 2.35 M 2.47 M 1.68 M 1.42 M 1.68 M 1.42 M 1.3 M 1.05 M 1.3 M 1.05 M 1.05 M 949 K 1.05 M 949 K 1.04 M 1.02 M 1.04 M 1.02 M 1.75 M 1.19 M 1.75 M 1.19 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company iBio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 263.04 0.49 % $ 465 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.41 2.15 % $ 3.41 B canadaCanada
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.53 6.02 % $ 678 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.09 3.74 % $ 139 M schweizSchweiz
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 8.61 0.16 % $ 2.05 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain